en تخصصي Special پژوهشي Research <span style="font-size:11pt"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span new="" roman="" style="font-family:" times="">Objective</span></b><b><span new="" roman="" style="font-family:" times="">:</span></b> <span new="" roman="" style="font-family:" times="">The current study aimed to compare the renal effects of Empagliflozin with Linagliptin combined with Metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span new="" roman="" style="font-family:" times="">Materials and Methods</span></b><b><span dir="RTL" new="" roman="" style="font-family:" times="">:</span></b><b> </b><span new="" roman="" style="font-family:" times="">We conducted a randomized clinical trial on diabetic patients aged over 18 years with chronic renal failure and an EGFR between 20 to 60 ml/minutes/1.73 m² corrected with the MDRD equation. Between January and December 2023, a total of 150 cases in Imam Hossein Hospital were randomized into two study arms of 75 cases receiving Empagliflozin (10 mg/day) and metformin or Linagliptin (5mg/day) and metformin for 6 months. The primary outcome was a change in chronic kidney disease (CKD) stage, while serum creatinine, fasting blood sugar (FBS), proteinuria, and blood pressure were evaluated at baseline, 3 and 6 months later.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span new="" roman="" style="font-family:" times="">Results</span></b><b><span dir="RTL" new="" roman="" style="font-family:" times="">:</span></b> <span new="" roman="" style="font-family:" times="">T</span><span new="" roman="" style="font-family:" times="">he mean age of participants was 62.20 (&plusmn; 4.45) years and 50% of them were females. Study indices including serum creatinine (<i>P</i>: 0.001), estimated glomerular filtration rate (eGFR) (<i>P</i>: 0.001), FBS (<i>P</i>: 0.001), HgA1c (<i>P</i>: 0.001), proteinuria (<i>P</i>: 0.001), and blood pressure (<i>P</i>: 0.001) reduced significantly over time in both groups. After adjustment for potential confounders, Empagliflozin reduced the level of serum creatinine independent of other factors.</span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Empagliflozin significantly reduces the level of serum creatinine compared to Linagliptin in patients with T2DM and chronic renal failure.</span></span></span></span></span></span></span><br> &nbsp; Chronic renal failure, Diabetes mellitus, Empagliflozin, Linagliptin 66 77 http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-409&slc_lang=en&sid=1 Reza Zeinabadi Noghabi 0009-0008-2099-4037 Yes Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Rojin Rouintan 0009-0009-4649-8346 No Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Tahereh Sabaghian 0000-0001-7689-8150 No Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Shayesteh Khalili 0000-0002-4008-7281 No Department of Endocrine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran